Activate Now
 
ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

How One LLND Treats Lyme disease and Co-infections Using Natural Medicine

12 Celebrities with Lyme Disease

Sexual Transmission of Lyme Disease: a Paradigm Shift

Single Low-magnitude Electric Pulse Successfully Fights Inflammation

Why Is Spicy Food Good for You?

Omega-3 fatty acids may help improve treatment, quality of life in cancer patients

How Essential Oils Can Help Improve Your Life

Parasites and Worms As Major Complicating Co-Factors In Lyme Disease Recovery

Ask the Doctor- Is it possible to be fully healed from or cured of Lyme Disease?

Anti-histamine drug Claritin can kill Borrelia by interfering with manganese utilization

 
Print Page
Email Article

Common Antibiotic Slows Bladder & Breast Cancer Cell Growth, Shows Therapeutic Promise

  [ 8 votes ]   [ Discuss This Article ]
www.ProHealth.com • January 20, 2011


“We find the results encouraging enough to pursue further study of nitroxoline for preclinical and clinical use in treating bladder carcinomas.”Prof. Jun O. Liu, Johns Hopkins

Researchers at the Johns Hopkins University School of Medicine have discovered that nitroxoline, an antibiotic commonly used around the world to treat urinary tract infections, can slow or stop the growth of human breast and bladder cancer cells by blocking the formation of new blood vessels.

The results, published Dec. 15 by the Journal of the National Cancer Institute,(1) suggest that nitroxoline shows promise as a potential therapeutic agent.

“Angiogenesis, the growth of new blood vessels, plays an important role in tumor growth and metastasis, so inhibiting angiogenesis is a promising strategy for developing new anticancer drugs,” says Jun O. Liu, PhD,  a professor of pharmacology and molecular sciences at Johns Hopkins.

The research team tested more than 177,000 chemical compounds and drugs for their ability to block the activity of a protein - called MetAP2 - implicated in the formation of new blood vessels. Previous research had shown that inhibiting MetAP2 leads to a cascade of molecular events that ultimately prevents vessel-forming cells from growing.

The team first tested 175,000 chemicals for their ability to block MetAP2 activity.

Of the 294 chemicals found to reduce MetAP2 activity by at least half, nitroxoline stood out in its ability to inhibit MetAP2 by more than 99% at low and safe concentration. “It was one of the most potent hits we identified from this chemical compound library,” says Dr. Liu.

At the same time, the team also tested 2,687 FDA-approved or commonly used drugs in the Johns Hopkins Drug Library for their ability to stop blood vessel-forming cells from growing.

The research team grew human umbilical vein endothelial cells, or HUVEC, in tiny wells and treated each well with a different drug from the Library. Of the 210 drugs that inhibited HUVEC growth by at least half, nitroxoline again stood out; it inhibited cell growth by 95.5% at the same concentration that blocked MetAP2.

The team then tested nitroxoline for its ability to stop blood vessel growth in mice.

They treated 10 mice with growth factors that encourage new vessel growth, then treated half with nitroxoline and the other half with only salt solution for comparison. After 10 days they discovered that untreated mice on the average developed 48.6 new vessels per microscope field - the area visible when looking at the tissue through a microscope - whereas nitroxoline-treated mice on average developed only 20 new vessels per microscope field.

“Because nitroxoline showed such a substantial inhibitory effect, we moved on to see if it would have an effect on tumors in mice,” says Liu.

Mice carrying transplanted human breast or bladder cancer cells were treated with nitroxoline injections every other day for a month in the case of breast cancer or every day for two weeks in the case of bladder cancer. Nitroxoline treatment reduced breast cancer cell tumor volume by 60% and bladder cancer cell tumor by more than 50%.

“There are limitations of this study, but we find the results encouraging enough to pursue further study of nitroxoline for preclinical and clinical use in treating bladder carcinomas,” says Dr. Liu.

_____

1. Full text: “Effect of nitroxoline on angiogenesis and growth of human bladder cancer,” Liu JO, et al. Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, Maryland, USA. [Email: joliu@jhu.edu]

Source: Johns Hopkins Medicine news release, Jan 20, 2011



Please Discuss This Article:   Post a Comment 



[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Save on Nutritional Supplement Orders

Featured Products

Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid

Natural Remedies

Herbal Inflammation Management for Whole Body Health Herbal Inflammation Management for Whole Body Health
Natural Relief for Soreness, Pain and Swelling – Putting Out the Fire
Are You Obtaining the Proper Enzymes? Are You Obtaining the Proper Enzymes?
Block Acid Reflux to Prevent Esophageal Problems! Block Acid Reflux to Prevent Esophageal Problems!
Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia Diagnosis
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS Diagnosis
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE  |  PRIVACY
CONTACT US
LIBRARY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing